Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI
Standard
Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI. / Wolfsgruber, Steffen; Jessen, Frank; Koppara, Alexander; Kleineidam, Luca; Schmidtke, Klaus; Frölich, Lutz; Kurz, Alexander; Schulz, Stefanie; Hampel, Harald; Heuser, Isabella; Peters, Oliver; Reischies, Friedel M; Jahn, Holger; Luckhaus, Christian; Hüll, Michael; Gertz, Hermann-Josef; Schröder, Johannes; Pantel, Johannes; Rienhoff, Otto; Rüther, Eckart; Henn, Fritz; Wiltfang, Jens; Maier, Wolfgang; Kornhuber, Johannes; Wagner, Michael.
in: NEUROLOGY, Jahrgang 84, Nr. 12, 24.03.2015, S. 1261-8.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Subjective cognitive decline is related to CSF biomarkers of AD in patients with MCI
AU - Wolfsgruber, Steffen
AU - Jessen, Frank
AU - Koppara, Alexander
AU - Kleineidam, Luca
AU - Schmidtke, Klaus
AU - Frölich, Lutz
AU - Kurz, Alexander
AU - Schulz, Stefanie
AU - Hampel, Harald
AU - Heuser, Isabella
AU - Peters, Oliver
AU - Reischies, Friedel M
AU - Jahn, Holger
AU - Luckhaus, Christian
AU - Hüll, Michael
AU - Gertz, Hermann-Josef
AU - Schröder, Johannes
AU - Pantel, Johannes
AU - Rienhoff, Otto
AU - Rüther, Eckart
AU - Henn, Fritz
AU - Wiltfang, Jens
AU - Maier, Wolfgang
AU - Kornhuber, Johannes
AU - Wagner, Michael
N1 - © 2015 American Academy of Neurology.
PY - 2015/3/24
Y1 - 2015/3/24
N2 - OBJECTIVE: To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective cognitive decline (SCD) in the memory domain predict abnormal CSF biomarkers of Alzheimer disease (AD).METHODS: We analyzed the multicenter baseline (cross-sectional) data of 245 patients with MCI. SCD was measured quantitatively with the Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated with self-experienced worsening of memory. Logistic regression models were used to examine associations between SCD and abnormal CSF biomarkers, taking into account objective memory impairment, depressive symptoms, and education as covariates.RESULTS: Abnormal CSF β-amyloid 1-42 (Aβ42) and more depressive symptoms were associated with higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF Aβ42 increased by an estimated 57% for a 1-SD increase in SMDS scores and was doubled in patients who had SMDS scores >4 or who reported memory concerns, respectively. In addition, both SCD measures predicted risk of having a biomarker signature indicative of prodromal AD defined as presence of low CSF Aβ42 together with either high CSF tau or CSF phosphorylated tau 181 levels.CONCLUSIONS: In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an improved operational assessment of SCD in MCI. This might be useful for sample enrichment strategies for increased likelihood of AD pathology.
AB - OBJECTIVE: To test whether, in individuals with mild cognitive impairment (MCI), different measures of subjective cognitive decline (SCD) in the memory domain predict abnormal CSF biomarkers of Alzheimer disease (AD).METHODS: We analyzed the multicenter baseline (cross-sectional) data of 245 patients with MCI. SCD was measured quantitatively with the Subjective Memory Decline Scale (SMDS) and qualitatively by assessing particular concerns associated with self-experienced worsening of memory. Logistic regression models were used to examine associations between SCD and abnormal CSF biomarkers, taking into account objective memory impairment, depressive symptoms, and education as covariates.RESULTS: Abnormal CSF β-amyloid 1-42 (Aβ42) and more depressive symptoms were associated with higher SMDS scores and with the report of memory concerns. Risk of abnormal CSF Aβ42 increased by an estimated 57% for a 1-SD increase in SMDS scores and was doubled in patients who had SMDS scores >4 or who reported memory concerns, respectively. In addition, both SCD measures predicted risk of having a biomarker signature indicative of prodromal AD defined as presence of low CSF Aβ42 together with either high CSF tau or CSF phosphorylated tau 181 levels.CONCLUSIONS: In MCI, specific aspects of SCD severity and quality are related to CSF biomarkers indicative of AD. This extends findings in pre-MCI samples and calls for an improved operational assessment of SCD in MCI. This might be useful for sample enrichment strategies for increased likelihood of AD pathology.
U2 - 10.1212/WNL.0000000000001399
DO - 10.1212/WNL.0000000000001399
M3 - SCORING: Journal article
C2 - 25716354
VL - 84
SP - 1261
EP - 1268
JO - NEUROLOGY
JF - NEUROLOGY
SN - 0028-3878
IS - 12
ER -
